Stryker (NYSE: SYK), a global leader in medical technologies, has announced its definitive agreement to acquire Inari Medical, Inc. (NASDAQ: NARI) for a total fully diluted equity value of approximately $4.9 billion. Inari, a company founded in 2011, holds a leading position in the peripheral vascular segment, specializing in venous thromboembolism (VTE) solutions.
Inari's innovative product portfolio, focused on mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, is highly complementary to Stryker’s neurovascular business. VTE affects up to 900,000 lives in the United States annually, with even more impacted worldwide. Inari’s solutions for VTE clot removal without the use of thrombolytic drugs address critical unmet patient needs.
The acquisition is anticipated to provide Stryker with an expanded portfolio to offer life-saving solutions to patients suffering from peripheral vascular diseases. This move is set to elevate the standard of care for VTE patients and accelerate Stryker’s impact in endovascular procedures. The transaction is expected to close by the end of the first quarter of 2025, subject to customary closing conditions.
The financial impacts of this acquisition on Stryker's 2025 results will be discussed in the upcoming fourth quarter 2024 earnings call scheduled for January 28, 2025.
Stryker’s acquisition of Inari reflects its commitment to expanding its medical technologies and providing innovative solutions to address critical healthcare needs. This strategic move positions Stryker to make a significant impact in the fast-growing peripheral vascular segment and further solidifies its position as a global leader in the medical technology industry. Following these announcements, the company's shares moved -1.7%, and are now trading at a price of $355.17. For the full picture, make sure to review Stryker's 8-K report.
